224 related articles for article (PubMed ID: 28387023)
1. Simultaneous usage of dementia medications and anticholinergics among Asians and Pacific Islanders.
Schultz BR; Takeshita J; Goebert D; Takeshita S; Lu BY; Guilloux A; Higa J
Psychogeriatrics; 2017 Nov; 17(6):423-429. PubMed ID: 28387023
[TBL] [Abstract][Full Text] [Related]
2. Anticholinergic medicines use among older adults before and after initiating dementia medicines.
Narayan SW; Pearson SA; Litchfield M; Le Couteur DG; Buckley N; McLachlan AJ; Zoega H
Br J Clin Pharmacol; 2019 Sep; 85(9):1957-1963. PubMed ID: 31046175
[TBL] [Abstract][Full Text] [Related]
3. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
[TBL] [Abstract][Full Text] [Related]
4. Use of anticholinergic medications by older adults with dementia.
Roe CM; Anderson MJ; Spivack B
J Am Geriatr Soc; 2002 May; 50(5):836-42. PubMed ID: 12028169
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.
Raina P; Santaguida P; Ismaila A; Patterson C; Cowan D; Levine M; Booker L; Oremus M
Ann Intern Med; 2008 Mar; 148(5):379-97. PubMed ID: 18316756
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
Kavirajan H; Schneider LS
Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
[TBL] [Abstract][Full Text] [Related]
8. Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM.
Byun J; Lee DY; Jeong CW; Kim Y; Rhee HY; Moon KW; Heo J; Hong Y; Kim WJ; Nam SJ; Choi HS; Park JI; Chun IK; Bak SH; Lee K; Byeon GH; Kim KL; Kim JA; Park YJ; Kim JH; Lee EJ; Lee SA; Kwon SO; Park SW; Kasani PH; Kim JK; Kim Y; Kim S; Jang JW
Sci Rep; 2022 Mar; 12(1):4451. PubMed ID: 35292697
[TBL] [Abstract][Full Text] [Related]
9. Summaries for patients. Drug treatment for patients with dementia: American College of Physicians and American Academy of Family Physicians recommendations.
Ann Intern Med; 2008 Mar; 148(5):I41. PubMed ID: 18316749
[No Abstract] [Full Text] [Related]
10. Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease.
Mantri S; Fullard M; Gray SL; Weintraub D; Hubbard RA; Hennessy S; Willis AW
JAMA Neurol; 2019 Jan; 76(1):41-49. PubMed ID: 30285047
[TBL] [Abstract][Full Text] [Related]
11. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
Ehret MJ; Chamberlin KW
Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885
[TBL] [Abstract][Full Text] [Related]
12. Galantamine improves sleep quality in patients with dementia.
Naharci MI; Ozturk A; Yasar H; Cintosun U; Kocak N; Bozoglu E; Tasci I; Doruk H
Acta Neurol Belg; 2015 Dec; 115(4):563-8. PubMed ID: 25777522
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.
Olazarán J; Carnero-Pardo C; Fortea J; Sánchez-Juan P; García-Ribas G; Viñuela F; Martínez-Lage P; Boada M
Alzheimers Res Ther; 2023 Aug; 15(1):130. PubMed ID: 37537656
[TBL] [Abstract][Full Text] [Related]
14. [Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina].
Rojas G; Demey I; Arizaga RL
Medicina (B Aires); 2013; 73(3):213-23. PubMed ID: 23732196
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
Noetzli M; Eap CB
Clin Pharmacokinet; 2013 Apr; 52(4):225-41. PubMed ID: 23408070
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
[TBL] [Abstract][Full Text] [Related]
17. [Use of acetylcholinesterase inhibitors and memantine in Alzheimer-type dementia].
Portela Romero M; Pombo Romero J; Bugarín González R; Tasende Souto M; Represa Veiga S
Rev Esp Salud Publica; 2005; 79(6):665-72. PubMed ID: 16457058
[TBL] [Abstract][Full Text] [Related]
18. Dementia medications in palliative care #174.
Morrison LJ; Liao S
J Palliat Med; 2008 May; 11(4):634-5. PubMed ID: 18454618
[No Abstract] [Full Text] [Related]
19. Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors.
Shega JW; Ellner L; Lau DT; Maxwell TL
J Palliat Med; 2009 Sep; 12(9):779-83. PubMed ID: 19622011
[TBL] [Abstract][Full Text] [Related]
20. [Current approaches to optimize treatment of dementia and Alzheimer's disease].
Kolykhalov IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):87-92. PubMed ID: 28635795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
